HSV-TK engineered donor lymphocytes add-backs reduce late mortality and improve survival of high risk acute leukemia after haplo-HSCT: Results of a phase II multicenter trial.

CICERI , FABIO;BONINI , MARIA CHIARA;Stanghellini MTL;BONDANZA , ATTILIO;Magnani Z;Perna S;Bernardi M;Peccatori J;Pescarollo A;Servida P;Crippa F;Callegaro L;Salomoni M;Turchetto L;Toma S;Bruzzi P;Castagna L;Santoro A;Apperley J;Slavin S;Colombi S;Gallo Stampino C;Bregni M;BORDIGNON, CLAUDIO

2005-01-01